ARRDC3 suppresses colorectal cancer progression through destabilizing the oncoprotein YAP

Area of Science:

• Oncology
• Molecular Biology
• Cell Biology

Background:

• Colorectal cancer (CRC) is a common digestive system malignancy with poorly understood tumorigenesis mechanisms.
• Arrestin-related domain-containing protein-3 (ARRDC3) is known to facilitate lysosome-mediated protein degradation.
• The Hippo pathway, regulated by YAP, is crucial in cancer development.

Purpose of the Study:

• To investigate the role of ARRDC3 in colorectal cancer progression.
• To elucidate the molecular mechanisms by which ARRDC3 affects CRC.
• To evaluate ARRDC3 as a potential therapeutic target for CRC.

Main Methods:

• Analysis of ARRDC3 expression in CRC specimens.
• Investigating the interaction between ARRDC3 and YAP.
• Assessing the impact of ARRDC3 on YAP expression and degradation.
• Evaluating the effect of ARRDC3 on CRC cell sensitivity to chemotherapy.
• Conservation studies from Drosophila to mammals.

Main Results:

• ARRDC3 expression is significantly downregulated in colorectal cancer tissues.
• ARRDC3 directly binds to and reduces the expression of the oncoprotein YAP.
• ARRDC3 exhibits an anti-oncogenic role by promoting YAP degradation, thus inhibiting CRC progression.
• ARRDC3 enhances the sensitivity of colorectal cancer cells to chemotherapeutic agents.
• The regulatory mechanism of the Hippo pathway by ARRDC3 is evolutionarily conserved.

Conclusions:

• ARRDC3 functions as a tumor suppressor in colorectal cancer.
• Targeting ARRDC3 may offer a novel therapeutic strategy for colorectal cancer treatment.
• Modulating ARRDC3 levels can potentially overcome chemoresistance in CRC.